Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Serruys

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 30, 2008
Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one yearPaul Barragan, Jean Fajadet, Imad Sheiban, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|January 8, 2026
Vessel-specific angiography-derived index of microcirculatory resistance in an all-comer population undergoing percutaneous coronary intervention, a PIONEER IV trial substudyChris Lenselink, Kim Ricken, Tsung-Ying Tsai, et al.
American Heart Journal|April 30, 2013
Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trialJimmy Machaalany, Luc Bilodeau, Rainer Hoffmann, et al.
The American Journal of Cardiology|May 3, 2011
Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stentsGiovanna Sarno, Lorenz Räber, Yoshinobu Onuma, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 8, 2025
Serial quantitative optical coherence tomography for luminal volume changes following either paclitaxel or sirolimus coated balloon in de novo small coronary artery lesionsAkihiro Tobe, Patrick Serruys, Kotaro Miyashita, et al.
European Heart Journal|October 11, 2005
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary interventionPeter R Sinnaeve, John Simes, Salim Yusuf, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|July 8, 2011
Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 yearsCihan Simsek, Michael Magro, Eric Boersma, et al.
Journal of Lipid Research|June 3, 2018
Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patientsSharda Anroedh, Mika Hilvo, K Martijn Akkerhuis, et al.
JACC. Cardiovascular Interventions|February 5, 2010
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions)Scot Garg, Patrick Serruys, Yoshinobu Onuma, et al.
The American Journal of Cardiology|August 10, 2015
Usefulness of Beta2-Microglobulin as a Predictor of All-Cause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study)Martin Möckel, Reinhold Muller, Julia Searle, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 30, 2008
Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one yearPaul Barragan, Jean Fajadet, Imad Sheiban, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|January 8, 2026
Vessel-specific angiography-derived index of microcirculatory resistance in an all-comer population undergoing percutaneous coronary intervention, a PIONEER IV trial substudyChris Lenselink, Kim Ricken, Tsung-Ying Tsai, et al.
American Heart Journal|April 30, 2013
Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trialJimmy Machaalany, Luc Bilodeau, Rainer Hoffmann, et al.
The American Journal of Cardiology|May 3, 2011
Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stentsGiovanna Sarno, Lorenz Räber, Yoshinobu Onuma, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|April 8, 2025
Serial quantitative optical coherence tomography for luminal volume changes following either paclitaxel or sirolimus coated balloon in de novo small coronary artery lesionsAkihiro Tobe, Patrick Serruys, Kotaro Miyashita, et al.
European Heart Journal|October 11, 2005
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary interventionPeter R Sinnaeve, John Simes, Salim Yusuf, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|July 8, 2011
Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 yearsCihan Simsek, Michael Magro, Eric Boersma, et al.
Journal of Lipid Research|June 3, 2018
Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patientsSharda Anroedh, Mika Hilvo, K Martijn Akkerhuis, et al.
JACC. Cardiovascular Interventions|February 5, 2010
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions)Scot Garg, Patrick Serruys, Yoshinobu Onuma, et al.
The American Journal of Cardiology|August 10, 2015
Usefulness of Beta2-Microglobulin as a Predictor of All-Cause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study)Martin Möckel, Reinhold Muller, Julia Searle, et al.
Pageof 11